Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Despite established guidance on dosing amounts and maintenance intervals, few pediatric patients ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study in Clinical Gastroenterology and Hepatology, the ...

To reduce the burden of individuals traveling long distances to receive hospital infusions or for families who are juggling care for several children and possibly older adult relatives, many ...

Patients with Crohn's disease who lose some or all of their initial therapeutic response to infliximab can benefit from dose intensification. Regueiro et al. retrospectively analyzed 293 patients with ...

Maintaining higher trough levels of infliximab (Remicade) of >7 μg/mL provided better control of inflammatory bowel disease (IBD) in hard-to-treat patients with no increase in infection risk, ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from ...

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study. Infliximab was the first anti-tumor necrosis ...